vimarsana.com

நரம்பியல் புற்றுநோயியல் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

University Hospitals using targeted radiation to improve post-brain cancer surgery results

Imvax Announces Publication of Phase 1b Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma in Clinical Cancer Research

Share this article Share this article PHILADELPHIA, Jan. 26, 2021 /PRNewswire/  Imvax, Inc., an emerging oncology leader that is revolutionizing immunotherapy for patients with Glioblastoma Multiforme (GBM), today announced publication of Phase 1b clinical trial results in Clinical Cancer Research, a journal of the American Association for Cancer Research. The article Phase1b Clinical Trial of IGV-001 for patients with Newly Diagnosed Glioblastoma is available online. IGV-001 is a first-in-class personalized immunotherapy that uses the patient s own tumor cells combined with an antisense molecule to induce a potent immune response. The treatment comprises irradiated autologous glioma cells with an antisense oligodeoxynucleotide directed at the IGF-1R (Insulin-like Growth Factor type one Receptor) named IMV-001. Delivered through an implantable and removable bio-diffusion chamber, antigenic products are released and initiate both an innate and adaptive response.

Miami Cancer Institute appoints deputy director

Miami Cancer Institute appoints deputy director Source/Disclosures Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS You ve successfully added to your alerts. You will receive an email when new content is published. Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Manmeet Ahluwalia, MD, FACP, MBA, has been appointed deputy director of Baptist Health’s Miami Cancer Institute. Ahluwalia a neuro-oncologist whose research focuses on primary brain tumors and brain metastases also will serve as chief scientific officer and chief of solid tumor medical oncology.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.